HHS Logo U.S. Department of Health & Human Services Divider arrow NIH logo National Institutes of Health Alt desc
Skip Over Navigation Links

Work with the SCTL

Cortical neurons derived from induced pluripotent stem cells

Cortical neurons derived from induced pluripotent stem cells: Red: neuronal marker TUJ1 (beta III tubulin). Green: cortical marker CUX-1. Blue: nuclear marker DAPI.

The Stem Cell Translation Laboratory (SCTL) is a state-of-the-art research facility within NCATS’ Division of Pre-Clinical Innovation that is dedicated to addressing the scientific and technological challenges in the induced pluripotent stem cell (iPSC) field. SCTL staff members work as a dynamic multidisciplinary team who apply their diverse scientific expertise to iPSC characterization and utilization. The SCTL features advanced equipment and resources not available to most laboratories, such as quantitative, high-throughput, small molecule screening; robotic automation of cell culture workflows; multiscale assay development; 3-D bioprinting; and integrated platforms to profile gene and protein expression and measure functional endpoints in standard cultures, as well as on the single cell level.

Areas of Interest

As part of a collaborative network of scientists, the SCTL is leading multidisciplinary efforts for the scalable expansion, controlled differentiation and translational utilization of iPSCs. As one of its goals, the SCTL will develop efficient and standardized methods to produce mature cells from iPSCs meeting strict quality-control and reproducibility standards. Establishing advanced iPSC protocols will be guided by the discovery, validation and dissemination of small molecule reagents that can replace expensive recombinant proteins, xenogenic material and undefined media components in cell differentiation protocols.

Who Can Apply?

NCATS is particularly interested in applications from early stage scientists (tenure-track and recently tenured) from the NIH intramural and extramural communities (e.g., academic institutions, other government research agencies) and from industry/for-profit organizations (e.g., biotech companies, pharmaceutical organizations). Selected applicants will work in partnership with SCTL staff to address specific biological and technical questions that currently impede the translation of iPSC research into treatments. Applicants will not be granted direct access to SCTL equipment and innovative technologies or provided with direct funding. In addition, all protocols, drugs and other products generated by the SCTL will be disseminated to the scientific community.

How to Collaborate

The SCTL is seeking new collaborations to help achieve common goals in iPSC biology in a faster and more coordinated fashion. Prospective collaborators are encouraged to connect with NCATS for timely notification when program updates are announced. Learn more about the proposal process.

Last updated: 10-06-2017
▲ Back to top